167 related articles for article (PubMed ID: 30640253)
1. Role of Cerebrospinal Fluid Biomarkers and (18)F-florbetapir PET Imaging in the Diagnosis of Primary Progressive Aphasia: A Retrospective Analysis.
Perini G; Cotta Ramusino M; Sinforiani E; Franciotta D; Trifirò G; Ceroni M; Costa A
Alzheimer Dis Assoc Disord; 2019; 33(3):282-284. PubMed ID: 30640253
[TBL] [Abstract][Full Text] [Related]
2. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia.
Santos-Santos MA; Rabinovici GD; Iaccarino L; Ayakta N; Tammewar G; Lobach I; Henry ML; Hubbard I; Mandelli ML; Spinelli E; Miller ZA; Pressman PS; O'Neil JP; Ghosh P; Lazaris A; Meyer M; Watson C; Yoon SJ; Rosen HJ; Grinberg L; Seeley WW; Miller BL; Jagust WJ; Gorno-Tempini ML
JAMA Neurol; 2018 Mar; 75(3):342-352. PubMed ID: 29309493
[TBL] [Abstract][Full Text] [Related]
3. Dual-phase
Kuo HC; Hsiao IT; Hsieh CJ; Huang CY; Huang KL; Wai YY; Chuang WL; Kung MP; Chu YC; Yen TC; Lin KJ; Huang CC
J Formos Med Assoc; 2017 Dec; 116(12):964-972. PubMed ID: 28434708
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia.
Santangelo R; Coppi E; Ferrari L; Bernasconi MP; Pinto P; Passerini G; Comi G; Magnani G
J Alzheimers Dis; 2015; 43(4):1429-40. PubMed ID: 25201781
[TBL] [Abstract][Full Text] [Related]
5. Amyloid PET Positivity in Different Primary Progressive Aphasia Phenotypes.
Beaufils E; Vercouillie J; Vierron E; Cottier JP; Camus V; Mondon K; Guilloteau D; Hommet C; Ribeiro MJ
Clin Nucl Med; 2018 Apr; 43(4):e103-e108. PubMed ID: 29504965
[TBL] [Abstract][Full Text] [Related]
6. CSF levels of Aβ1-38/Aβ1-40/Aβ1-42 and (11)C PiB-PET studies in three clinical variants of primary progressive aphasia and Alzheimer's disease.
Ikeda M; Tashiro Y; Takai E; Kurose S; Fugami N; Tsuda K; Arisaka Y; Kodaira S; Fujita Y; Makioka K; Mizuno Y; Shimada H; Harigaya Y; Takatama M; Amari M; Yamazaki T; Yamaguchi H; Higuchi T; Okamoto K; Tsushima Y; Ikeda Y
Amyloid; 2014 Dec; 21(4):238-45. PubMed ID: 25139672
[TBL] [Abstract][Full Text] [Related]
7. Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias.
Steinacker P; Semler E; Anderl-Straub S; Diehl-Schmid J; Schroeter ML; Uttner I; Foerstl H; Landwehrmeyer B; von Arnim CA; Kassubek J; Oeckl P; Huppertz HJ; Fassbender K; Fliessbach K; Prudlo J; Roßmeier C; Kornhuber J; Schneider A; Volk AE; Lauer M; Danek A; Ludolph AC; Otto M;
Neurology; 2017 Mar; 88(10):961-969. PubMed ID: 28179468
[TBL] [Abstract][Full Text] [Related]
8. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.
Toledo JB; Bjerke M; Da X; Landau SM; Foster NL; Jagust W; Jack C; Weiner M; Davatzikos C; Shaw LM; Trojanowski JQ;
JAMA Neurol; 2015 May; 72(5):571-81. PubMed ID: 25822737
[TBL] [Abstract][Full Text] [Related]
9. Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasias.
Mendes A; Bertrand A; Lamari F; Colliot O; Routier A; Godefroy O; Etcharry-Bouyx F; Moreaud O; Pasquier F; Couratier P; Bennys K; Vercelletto M; Martinaud O; Laurent B; Pariente J; Puel M; Epelbaum S; Belliard S; Kaaouana T; Fillon L; Chupin M; Dubois B; Teichmann M;
Neurology; 2018 Mar; 90(12):e1057-e1065. PubMed ID: 29444966
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.
Paraskevas GP; Kasselimis D; Kourtidou E; Constantinides V; Bougea A; Potagas C; Evdokimidis I; Kapaki E
J Alzheimers Dis; 2017; 55(4):1453-1461. PubMed ID: 27858708
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
12. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia.
Bergeron D; Gorno-Tempini ML; Rabinovici GD; Santos-Santos MA; Seeley W; Miller BL; Pijnenburg Y; Keulen MA; Groot C; van Berckel BNM; van der Flier WM; Scheltens P; Rohrer JD; Warren JD; Schott JM; Fox NC; Sanchez-Valle R; Grau-Rivera O; Gelpi E; Seelaar H; Papma JM; van Swieten JC; Hodges JR; Leyton CE; Piguet O; Rogalski EJ; Mesulam MM; Koric L; Kristensen N; Pariente J; Dickerson B; Mackenzie IR; Hsiung GR; Belliard S; Irwin DJ; Wolk DA; Grossman M; Jones M; Harris J; Mann D; Snowden JS; Chrem-Mendez P; Calandri IL; Amengual AA; Miguet-Alfonsi C; Magnin E; Magnani G; Santangelo R; Deramecourt V; Pasquier F; Mattsson N; Nilsson C; Hansson O; Keith J; Masellis M; Black SE; Matías-Guiu JA; Cabrera-Martin MN; Paquet C; Dumurgier J; Teichmann M; Sarazin M; Bottlaender M; Dubois B; Rowe CC; Villemagne VL; Vandenberghe R; Granadillo E; Teng E; Mendez M; Meyer PT; Frings L; Lleó A; Blesa R; Fortea J; Seo SW; Diehl-Schmid J; Grimmer T; Frederiksen KS; Sánchez-Juan P; Chételat G; Jansen W; Bouchard RW; Laforce RJ; Visser PJ; Ossenkoppele R
Ann Neurol; 2018 Nov; 84(5):729-740. PubMed ID: 30255971
[TBL] [Abstract][Full Text] [Related]
14. Data-driven subtypes of mixed semantic-logopenic primary progressive aphasia: Linguistic features, biomarker profiles and brain metabolic patterns.
Mazzeo S; Morinelli C; Polito C; Giacomucci G; Moschini V; Ingannato A; Balestrini J; Frigerio D; Emiliani F; Galdo G; Crucitti C; Piazzesi D; Bagnoli S; Padiglioni S; Berti V; Sorbi S; Nacmias B; Bessi V
J Neurol Sci; 2024 May; 460():122998. PubMed ID: 38615405
[TBL] [Abstract][Full Text] [Related]
15. Amyloid pet in primary progressive aphasia: case series and systematic review of the literature.
Villarejo-Galende A; Llamas-Velasco S; Gómez-Grande A; Puertas-Martín V; Contador I; Sarandeses P; González-Sánchez M; Trincado R; Pilkington P; Ruiz-Solis S; Pérez-Martínez DA; Herrero-San Martín A
J Neurol; 2017 Jan; 264(1):121-130. PubMed ID: 27815682
[TBL] [Abstract][Full Text] [Related]
16. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
[TBL] [Abstract][Full Text] [Related]
17. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
[TBL] [Abstract][Full Text] [Related]
18. Differential chemokine alteration in the variants of primary progressive aphasia-a role for neuroinflammation.
Sogorb-Esteve A; Swift IJ; Woollacott IOC; Warren JD; Zetterberg H; Rohrer JD
J Neuroinflammation; 2021 Oct; 18(1):224. PubMed ID: 34602080
[TBL] [Abstract][Full Text] [Related]
19. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease.
Louwersheimer E; Keulen MA; Steenwijk MD; Wattjes MP; Jiskoot LC; Vrenken H; Teunissen CE; van Berckel BN; van der Flier WM; Scheltens P; van Swieten JC; Pijnenburg YA
J Alzheimers Dis; 2016; 51(2):581-90. PubMed ID: 26890751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
